Rationale and protocol for a randomized waitlist controlled trial of videoconference delivered cognitive behaviour therapy for insomnia (CBT-I) to improve perceived cognitive impairment (PCI) among cancer survivors.


Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
04 2021
Historique:
received: 26 10 2020
revised: 11 01 2021
accepted: 06 02 2021
pubmed: 16 2 2021
medline: 28 9 2021
entrez: 15 2 2021
Statut: ppublish

Résumé

Perceived cognitive impairment (PCI) and sleep disturbances (such as insomnia) are commonly reported barriers preventing cancer survivors from resuming normal functioning. Cognitive-behaviour therapy for insomnia (CBT-I) is the treatment of choice for insomnia among cancer survivors. Literature suggests that treatment with CBT-I may lead to an improvement in PCI, but this needs to be tested in a sample of patients with PCI at study entry with cognitive impairments as the primary study outcome. Here we describe the design of a clinical trial to evaluate the efficacy of videoconference-delivered CBT-I for the improvement of PCI among cancer survivors. This project is a randomized waitlist-controlled trial with a recruitment target of 124 adult cancer survivors (solid tumors and hematological malignancies) who have completed primary treatment at least 6 months prior, report PCI and meet criteria for insomnia disorder. Participants will complete assessments at baseline, 4 weeks (mid-treatment), 8 weeks (post treatment), and 3 and 6 months post-treatment. The primary outcome is the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog). Treatment of PCI in cancer patients is a priority for clinicians, researchers, and patients. This research will increase our understanding of the mechanisms of cognitive impairment associated with cancer, and potentially expand currently available treatment options.

Identifiants

pubmed: 33588077
pii: S1551-7144(21)00058-6
doi: 10.1016/j.cct.2021.106322
pii:
doi:

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106322

Subventions

Organisme : CIHR
ID : PJT 162428
Pays : Canada

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Sheila N Garland (SN)

Department of Psychology, Faculty of Science, Memorial University, Newfoundland and Labrador, Canada; Discipline of Oncology, Faculty of Medicine, Memorial University, Newfoundland and Labrador, Canada; Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada. Electronic address: sheila.garland@mun.ca.

Josée Savard (J)

École de psychologie, Université Laval and CHU de Québec-Université Laval Research Center, Quebec, Canada.

Kathryn Dalton (K)

Department of Psychology, Faculty of Science, Memorial University, Newfoundland and Labrador, Canada.

Nyissa A Walsh (NA)

Department of Psychology, Faculty of Science, Memorial University, Newfoundland and Labrador, Canada; Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada.

Melanie Seal (M)

Discipline of Oncology, Faculty of Medicine, Memorial University, Newfoundland and Labrador, Canada.

Joshua Rash (J)

Department of Psychology, Faculty of Science, Memorial University, Newfoundland and Labrador, Canada.

Sondria Browne (S)

Department of Psychology, Faculty of Science, Memorial University, Newfoundland and Labrador, Canada.

Robin Urquhart (R)

Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Canada.

John Thoms (J)

Discipline of Oncology, Faculty of Medicine, Memorial University, Newfoundland and Labrador, Canada.

Veeresh Gadag (V)

Division of Community Health and Humanities, Faculty of Medicine, Memorial University, Newfoundland and Labrador, Canada.

Kara Laing (K)

Discipline of Oncology, Faculty of Medicine, Memorial University, Newfoundland and Labrador, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH